AU2007281531B2 - Use of poloxamer for the prevention and/or treatment of heart failure - Google Patents

Use of poloxamer for the prevention and/or treatment of heart failure Download PDF

Info

Publication number
AU2007281531B2
AU2007281531B2 AU2007281531A AU2007281531A AU2007281531B2 AU 2007281531 B2 AU2007281531 B2 AU 2007281531B2 AU 2007281531 A AU2007281531 A AU 2007281531A AU 2007281531 A AU2007281531 A AU 2007281531A AU 2007281531 B2 AU2007281531 B2 AU 2007281531B2
Authority
AU
Australia
Prior art keywords
poloxamer
heart failure
administered
patient
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007281531A
Other languages
English (en)
Other versions
AU2007281531A1 (en
Inventor
Bruce Edward Markham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phrixus Pharmaceuticals Inc
Original Assignee
Phrixus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phrixus Pharmaceuticals Inc filed Critical Phrixus Pharmaceuticals Inc
Publication of AU2007281531A1 publication Critical patent/AU2007281531A1/en
Application granted granted Critical
Publication of AU2007281531B2 publication Critical patent/AU2007281531B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007281531A 2006-08-01 2007-08-01 Use of poloxamer for the prevention and/or treatment of heart failure Ceased AU2007281531B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83472806P 2006-08-01 2006-08-01
US60/834,728 2006-08-01
PCT/US2007/017182 WO2008016640A2 (en) 2006-08-01 2007-08-01 Use of poloxamer for the prevention and/or treatment of heart failure

Publications (2)

Publication Number Publication Date
AU2007281531A1 AU2007281531A1 (en) 2008-02-07
AU2007281531B2 true AU2007281531B2 (en) 2013-07-04

Family

ID=38805633

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007281531A Ceased AU2007281531B2 (en) 2006-08-01 2007-08-01 Use of poloxamer for the prevention and/or treatment of heart failure

Country Status (7)

Country Link
US (1) US9155758B2 (cg-RX-API-DMAC10.html)
EP (1) EP2046348B1 (cg-RX-API-DMAC10.html)
JP (2) JP5537152B2 (cg-RX-API-DMAC10.html)
CN (4) CN101534843A (cg-RX-API-DMAC10.html)
AU (1) AU2007281531B2 (cg-RX-API-DMAC10.html)
CA (1) CA2659909A1 (cg-RX-API-DMAC10.html)
WO (1) WO2008016640A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101534843A (zh) 2006-08-01 2009-09-16 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
WO2008124088A2 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
WO2011156389A2 (en) * 2010-06-07 2011-12-15 The Regents Of The University Of California The islet amyloid polypeptide toxic oligomer is a biomarker of heart or kidney failure in type-2 diabetes mellitus
JP2016533377A (ja) * 2013-10-16 2016-10-27 マスト セラピューティクス インコーポレイテッドＭａｓｔ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 利尿薬によって誘発される血漿量の変化
AU2015287993B2 (en) 2014-07-07 2020-10-29 Liferaft Biosciences, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
WO2016007542A1 (en) * 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
JP7867990B2 (ja) * 2020-07-09 2026-06-01 ムスク・ファウンデイション・フォー・リサーチ・ディベロップメント 傷害から細胞を保護する方法
CN111973623B (zh) * 2020-08-06 2022-04-05 温州医科大学 心力衰竭靶向治疗的速释制剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198211A (en) 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
EP0576612B1 (en) 1991-03-19 1999-12-01 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
WO1992022202A1 (en) 1991-06-03 1992-12-23 Alpha Therapeutics Corporation Thrombolytic and perfluorochemical treatment for myocardial infraction
US5605687A (en) 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
AU1312800A (en) 1998-10-09 2000-05-01 Cytrx Corporation Method and composition for treating ischemia and sickle cell anemia
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6761824B2 (en) 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
EP1335707A4 (en) 2000-10-24 2005-07-06 Smithkline Beecham Corp NEW CARVEDILOL FORMULATIONS
US7341552B2 (en) 2002-03-15 2008-03-11 The University Of Texas System Board Of Regents Gene sets for glioma classification
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
WO2006037031A2 (en) 2004-09-27 2006-04-06 Valentis, Inc. Formulations and methods for treatment of inflammatory diseases
US20060121016A1 (en) 2004-10-18 2006-06-08 Lee Raphael C Methods and compositions for treatment of free radical injury
EP1853280B1 (en) 2005-02-25 2012-02-22 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease
PL1861080T3 (pl) 2005-03-21 2010-10-29 Santhera Pharmaceuticals Schweiz Ag Idebenon do leczenia dystrofii mięśniowych
JP5745210B2 (ja) 2006-02-03 2015-07-08 ニコックス サイエンス アイルランド 筋ジストロフィーの治療用薬剤のニトロオキシ誘導体の使用
CN101534843A (zh) 2006-08-01 2009-09-16 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
WO2008124088A2 (en) 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
WO2009078978A2 (en) 2007-12-14 2009-06-25 Phrixus Pharmaceuticals, Inc. Compositions containing polyglycidol-based polymers and uses thereof
EP2234625B8 (en) 2007-12-17 2013-10-30 The Regents of the University of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
WO2011066201A2 (en) 2009-11-25 2011-06-03 The Regents Of The University Of Michigan Methods and systems for treating and preventing cardiac injury in dystrophic subjects

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Schaer G L et al, American Heart Association, Vol. 94, No. 3, 1 January 1996 *
Toth K et al, Clinical Hemorheology and Microcirculation, Vol. 17, No. 2, Pages 117-125, 1 January 1997 *
Yasuda Soichiro et al, Nature, Vol. 436, No. 7053, Pages 1025-1029, 18 August 2005 *

Also Published As

Publication number Publication date
US20090246162A1 (en) 2009-10-01
EP2046348B1 (en) 2015-07-22
CN103222984A (zh) 2013-07-31
WO2008016640A2 (en) 2008-02-07
CN101534843A (zh) 2009-09-16
AU2007281531A1 (en) 2008-02-07
JP2013253103A (ja) 2013-12-19
CN103271935A (zh) 2013-09-04
WO2008016640A3 (en) 2009-02-05
CN102218077A (zh) 2011-10-19
JP5537152B2 (ja) 2014-07-02
US9155758B2 (en) 2015-10-13
CA2659909A1 (en) 2008-02-07
EP2046348A2 (en) 2009-04-15
JP2009545595A (ja) 2009-12-24

Similar Documents

Publication Publication Date Title
US9155758B2 (en) Treatment of chronic progressive heart failure
ES2392596T3 (es) Neurregulina en el tratamiento de enfermedades cardiacas
AU2013259526B2 (en) New methods
EP3463574B1 (en) Compositions and methods for treating pulmonary vascular disease
US20110021475A1 (en) Compositions And Methods for Treatment Of Fibrosis
JP6151123B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
US20090176772A1 (en) Method of reversing left ventricular remodeling
CN112752582A (zh) 利用达格列净治疗射血分数降低的心力衰竭的方法
AU2010214636A1 (en) Compositions and methods for treating and preventing cardiomyopathy and heart disease
JP2026082950A (ja) 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ
Melian et al. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension
AU2015335855A1 (en) Method of treating patients with hepatorenal syndrome type 1
JP2022526914A5 (cg-RX-API-DMAC10.html)
US20250144179A1 (en) Peptide hormone to prevent or treat vasospasm, brain injury or cerebral edema
Sánchez-Aguilar et al. Research Article Nonclassical Axis of the Renin-Angiotensin System and Neprilysin: Key Mediators That Underlie the Cardioprotective Effect of PPAR-Alpha Activation during Myocardial Ischemia in a Metabolic Syndrome Model
Arieff Diabetic nephropathy and treatment of hypertension
Chow et al. Silent meningioma–a rare cause of stroke in post-cardiopulmonary bypass patients
Gurevich et al. Effects of angiotensin receptor blockade on haemodynamics and gene expression after myocardial infarction
Diamond et al. Antihypertensive drugs and the heart
EA052076B1 (ru) Комбинация зиботентана и дапаглифлозина для лечения хронического заболевания почек
HK40006997B (en) Compositions and methods for treating pulmonary vascular disease
HK40090059A (en) Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
KR20190060642A (ko) 심부전의 예방 또는 치료용 의약

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired